Oncolytics Biotech Stock Price, News & Analysis (TSE:ONC)

C$1.00 -0.05 (-4.76 %)
(As of 01/17/2018 04:00 PM ET)
Previous CloseC$1.05
Today's RangeC$0.99 - C$1.10
52-Week RangeC$0.25 - C$1.13
Volume387,015 shs
Average Volume690,209 shs
Market CapitalizationC$147.74 million
P/E Ratio-7.69
Dividend YieldN/A
Beta1.13

About Oncolytics Biotech (TSE:ONC)

Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company's clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.

Receive ONC News and Ratings via Email

Sign-up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorHealthcare
SymbolTSE:ONC
CUSIPN/A
Phone+1-403-6707380

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-7.69230769230769
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSC($0.13)
Net IncomeN/A
Net MarginsN/A
Return on Equity-91.52%
Return on Assets-74.32%

Miscellaneous

EmployeesN/A
Outstanding Shares140,701,000

Oncolytics Biotech (TSE:ONC) Frequently Asked Questions

What is Oncolytics Biotech's stock symbol?

Oncolytics Biotech trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC."

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech Inc. (TSE:ONC) posted its quarterly earnings results on Wednesday, November, 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01. View Oncolytics Biotech's Earnings History.

When will Oncolytics Biotech make its next earnings announcement?

Oncolytics Biotech is scheduled to release their next quarterly earnings announcement on Friday, March, 9th 2018. View Earnings Estimates for Oncolytics Biotech.

Where is Oncolytics Biotech's stock going? Where will Oncolytics Biotech's stock price be in 2018?

2 Wall Street analysts have issued 12-month price objectives for Oncolytics Biotech's stock. Their forecasts range from C$1.50 to C$1.50. On average, they anticipate Oncolytics Biotech's stock price to reach C$1.50 in the next twelve months. View Analyst Ratings for Oncolytics Biotech.

Who are some of Oncolytics Biotech's key competitors?

Who are Oncolytics Biotech's key executives?

Oncolytics Biotech's management team includes the folowing people:

  • Wayne F. Pisano, Chairman of the Board
  • Matthew C. Coffey Ph.D., President, Chief Executive Officer, Chief Operating Officer, Director
  • Kirk J. Look, Chief Financial Officer
  • George M. Gill M.D., Senior Vice President - Regulatory Affairs & Chief Safety Officer
  • Mary Ann Dillahunty J.D., Vice President - Intellectual Property
  • Andres A. Gutierrez, Chief Medical Officer
  • Alan J. Tuchman M.D., Chief Neuro Oncology Research Officer (Age 69)
  • Deborah M. Brown, Director
  • Angela Frances Holtham, Director
  • Edwin Levy Ph.D., Director

How do I buy Oncolytics Biotech stock?

Shares of Oncolytics Biotech and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Oncolytics Biotech's stock price today?

One share of Oncolytics Biotech stock can currently be purchased for approximately C$1.00.

How big of a company is Oncolytics Biotech?

Oncolytics Biotech has a market capitalization of C$147.74 million.

How can I contact Oncolytics Biotech?

Oncolytics Biotech's mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The company can be reached via phone at +1-403-6707380.


MarketBeat Community Rating for Oncolytics Biotech (ONC)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  78 (Vote Outperform)
Underperform Votes:  42 (Vote Underperform)
Total Votes:  120
MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Oncolytics Biotech (TSE:ONC) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: C$1.50C$1.50C$1.50C$1.50
Price Target Upside: 50.00% upside50.00% upside50.00% upside50.00% upside

Oncolytics Biotech (TSE:ONC) Consensus Price Target History

Price Target History for Oncolytics Biotech (TSE:ONC)

Oncolytics Biotech (TSE:ONC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
4/13/2017BMO Capital MarketsBoost Price TargetOutperformC$1.00 -> C$1.50View Rating Details
4/13/2017Royal Bank of CanadaBoost Price TargetOutperformC$1.00 -> C$1.50View Rating Details
(Data available from 1/17/2016 forward)

Earnings

Oncolytics Biotech (TSE:ONC) Earnings History and Estimates Chart

Earnings by Quarter for Oncolytics Biotech (TSE:ONC)

Oncolytics Biotech (TSE ONC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/9/2018        
11/8/2017Q3 2017C($0.03)C($0.02)ViewN/AView Earnings Details
8/3/2017Q2 2017C($0.03)C($0.03)ViewN/AView Earnings Details
5/5/2017Q1 2017C($0.03)C($0.03)ViewN/AView Earnings Details
3/10/2017Q4 2016C($0.04)ViewN/AView Earnings Details
11/3/2016Q3 2016C($0.03)ViewN/AView Earnings Details
8/4/2016Q2 2016C($0.02)ViewN/AView Earnings Details
5/6/2016Q1 2016C($0.03)ViewN/AView Earnings Details
3/11/2016Q4 2015C($0.03)ViewN/AView Earnings Details
11/5/2015Q3 2015C($0.02)ViewN/AView Earnings Details
8/6/2015Q2 2015C($0.03)ViewN/AView Earnings Details
5/7/2015Q1 2015C($0.04)ViewN/AView Earnings Details
3/13/2015Q4 2014C($0.04)ViewN/AView Earnings Details
11/6/2014Q3 2014C($0.05)ViewN/AView Earnings Details
8/7/2014Q2 14C($0.07)C($0.05)ViewN/AView Earnings Details
5/8/2014Q1 2014C($0.06)ViewN/AView Earnings Details
3/13/2014Q4 2013C($0.07)ViewN/AView Earnings Details
11/7/2013Q3 13C($0.07)C($0.07)ViewN/AView Earnings Details
8/1/2013Q2 2013C($0.06)ViewN/AView Earnings Details
5/9/2013Q1 2013C($0.11)C($0.08)ViewN/AView Earnings Details
3/14/2013Q4 2012C($0.10)C($0.11)ViewN/AView Earnings Details
11/8/2012Q3 2012C($0.13)C($0.12)ViewN/AView Earnings Details
8/2/2012Q2 2012C($0.12)C($0.13)ViewN/AView Earnings Details
5/10/2012Q1 2012C($0.10)C($0.11)ViewN/AView Earnings Details
3/15/2012Q4 2011C($0.10)C($0.16)ViewN/AView Earnings Details
11/10/2011Q3 2011C($0.07)C($0.09)ViewN/AView Earnings Details
7/28/2011Q2 2011C($0.07)C($0.09)ViewN/AView Earnings Details
5/12/2011Q1 2011C($0.07)C($0.06)ViewN/AView Earnings Details
3/17/2011Q4 2010C($0.06)C($0.12)ViewN/AView Earnings Details
11/10/2010Q3 2010C($0.08)C($0.07)ViewN/AView Earnings Details
7/29/2010Q2 2010C($0.07)C($0.07)ViewN/AView Earnings Details
5/12/2010Q1 2010C($0.08)C$0.07ViewN/AView Earnings Details
11/5/2009Q3 2009C($0.09)C($0.05)ViewN/AView Earnings Details
7/29/2009Q2 2009C($0.09)C($0.09)ViewN/AView Earnings Details
5/5/2009Q1 2009C($0.11)C($0.09)ViewN/AView Earnings Details
11/4/2008Q3 2008C$0.10ViewN/AView Earnings Details
7/29/2008Q2 2008C($0.13)ViewN/AView Earnings Details
4/30/2008Q1 2008C($0.08)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Oncolytics Biotech (TSE:ONC) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Oncolytics Biotech (TSE:ONC)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Oncolytics Biotech (TSE ONC) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Oncolytics Biotech (TSE:ONC)

Oncolytics Biotech (TSE ONC) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/26/2015Angela Frances HolthamDirectorBuy5,000C$0.89C$4,450.00
5/12/2015Wayne PisanoDirectorBuy20,000C$0.76C$15,150.00
(Data available from 1/1/2013 forward)

Headlines

Oncolytics Biotech (TSE ONC) News Headlines

Source:
DateHeadline
BRIEF-Oncolytics Biotech Receives Final Advice Letter From European Medicines Agency For Reolysin In Metastatic Breast CancerBRIEF-Oncolytics Biotech Receives Final Advice Letter From European Medicines Agency For Reolysin In Metastatic Breast Cancer
www.reuters.com - December 5 at 11:55 AM
Oncolytics Biotech® Establishes Scientific Advisory Board Focused ... - PR Newswire (press release)Oncolytics Biotech® Establishes Scientific Advisory Board Focused ... - PR Newswire (press release)
www.prnewswire.com - November 30 at 10:50 AM
Oncolytics Biotech (ONCYF) Updates On Clinical Data & Development Plan - SlideshowOncolytics Biotech (ONCYF) Updates On Clinical Data & Development Plan - Slideshow
seekingalpha.com - November 21 at 9:00 AM
BRIEF-Oncolytics Biotech Inc reports qtrly share of $0.02BRIEF-Oncolytics Biotech Inc reports qtrly share of $0.02
www.reuters.com - November 9 at 10:06 AM
Oncolytics Biotech® Appoints Deborah Brown to Board of Directors - PR Newswire (press release)Oncolytics Biotech® Appoints Deborah Brown to Board of Directors - PR Newswire (press release)
www.prnewswire.com - November 4 at 8:31 AM
Sorrento Therapeutics: Buy, Sell Or Hold After Its Big Rally?Sorrento Therapeutics: Buy, Sell Or Hold After Its Big Rally?
seekingalpha.com - October 14 at 6:26 AM
Form 6-K ONCOLYTICS BIOTECH INC For: Oct 11 - StreetInsider.comForm 6-K ONCOLYTICS BIOTECH INC For: Oct 11 - StreetInsider.com
www.streetinsider.com - October 13 at 7:44 AM
Oncolytics’ (ONCYF) End of Phase II MeetingOncolytics’ (ONCYF) End of Phase II Meeting
finance.yahoo.com - September 22 at 7:21 AM
BRIEF-Oncolytics announces successful end-of-Phase 2 meeting with FDA for reolysinBRIEF-Oncolytics announces successful end-of-Phase 2 meeting with FDA for reolysin
www.reuters.com - September 19 at 6:11 AM
BRIEF-Oncolytics Biotech announces first patient treated in Muk Eleven studyBRIEF-Oncolytics Biotech announces first patient treated in Muk Eleven study
www.reuters.com - September 14 at 8:46 AM
Oncolytics Biotech® Announces the Presentation of REOLYSIN ... - PR Newswire (press release)Oncolytics Biotech® Announces the Presentation of REOLYSIN ... - PR Newswire (press release)
www.prnewswire.com - September 12 at 8:40 AM
Oncolytics’ (ONCYF) Second Quarter ResultsOncolytics’ (ONCYF) Second Quarter Results
finance.yahoo.com - August 15 at 5:44 AM
FY2017 EPS Estimates for Oncolytics Biotech Inc. (ONC) Decreased by AnalystFY2017 EPS Estimates for Oncolytics Biotech Inc. (ONC) Decreased by Analyst
www.americanbankingnews.com - August 10 at 10:42 AM
Oncolytics Biotech® Inc. Announces 2017 Second Quarter ResultsOncolytics Biotech® Inc. Announces 2017 Second Quarter Results
finance.yahoo.com - August 4 at 6:40 AM
Oncolytics reports 2Q lossOncolytics reports 2Q loss
finance.yahoo.com - August 4 at 6:40 AM
Oncolytics Biotech® Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference - PR Newswire (press release)Oncolytics Biotech® Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference - PR Newswire (press release)
www.prnewswire.com - August 2 at 6:37 AM
BRIEF-Oncolytics Biotech granted end-of-phase 2 meeting with FDABRIEF-Oncolytics Biotech granted end-of-phase 2 meeting with FDA
www.reuters.com - July 27 at 6:04 AM
Oncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 CongressOncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 Congress
finance.yahoo.com - July 27 at 6:04 AM
Oncolytics (ONCYF) Raises CAD$11 MillionOncolytics (ONCYF) Raises CAD$11 Million
finance.yahoo.com - July 6 at 7:41 AM
Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (US) Inc. - PR Newswire (press release)Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (US) Inc. - PR Newswire (press release)
www.prnewswire.com - July 1 at 6:22 AM
Oncolytics Biotech® Inc. Opens US Based Office in San Diego - PR Newswire (press release)Oncolytics Biotech® Inc. Opens US Based Office in San Diego - PR Newswire (press release)
www.prnewswire.com - June 29 at 12:36 AM
Oncolytics Biotech® Prices Public Offering of UnitsOncolytics Biotech® Prices Public Offering of Units
www.prnewswire.com - May 24 at 7:16 PM
Oncolytics Biotech Prices Public Offering of UnitsOncolytics Biotech Prices Public Offering of Units
www.marketwatch.com - May 24 at 7:16 PM
BRIEF-Oncolytics Biotech prices public offering of unitsBRIEF-Oncolytics Biotech prices public offering of units
www.reuters.com - May 24 at 7:15 PM
FDA Grants Fast Track Status to Oncolytics Reolysin for Breast CancerFDA Grants Fast Track Status to Oncolytics' Reolysin for Breast Cancer
www.baystreet.ca - May 8 at 12:09 PM
BRIEF-Oncolytics Biotech Inc announces FDA fast track designation for ReolysinBRIEF-Oncolytics Biotech Inc announces FDA fast track designation for Reolysin
www.reuters.com - May 8 at 12:09 PM
Oncolytics Biotech® Inc. Announces Voting Results from its Annual Meeting of Shareholders - PR Newswire (press release)Oncolytics Biotech® Inc. Announces Voting Results from its Annual Meeting of Shareholders - PR Newswire (press release)
www.prnewswire.com - May 5 at 7:20 PM
Oncolytics Biotech® Inc. Announces 2017 First Quarter ResultsOncolytics Biotech® Inc. Announces 2017 First Quarter Results
www.prnewswire.com - May 5 at 8:53 AM
Oncolytics reports 1Q lossOncolytics reports 1Q loss
marketbeat.com - May 5 at 7:18 AM
Oncolytics Biotech announces registration pathway and clinical development plan - Seeking AlphaOncolytics Biotech announces registration pathway and clinical development plan - Seeking Alpha
seekingalpha.com - April 14 at 6:40 PM
Biopharmaceutical Market Scope Rising With Escalating Health Concerns - IndustryARCBiopharmaceutical Market Scope Rising With Escalating Health Concerns - IndustryARC
globenewswire.com - March 28 at 6:48 PM
BRIEF-Shanghai Shyndec Pharmas unit fined by food and drug authorities - ReutersBRIEF-Shanghai Shyndec Pharma's unit fined by food and drug authorities - Reuters
www.reuters.com - March 4 at 12:03 AM
Global Oncolytic Virus Landscape 2017: Key Players, Key Technologies, Projects, Business Deals and Private and ... - GlobeNewswire (press release)Global Oncolytic Virus Landscape 2017: Key Players, Key Technologies, Projects, Business Deals and Private and ... - GlobeNewswire (press release)
globenewswire.com - January 31 at 5:48 AM
Oncolytics Biotech® Inc. Appoints Dr. Matt Coffey to the Role of President and CEO - PR Newswire (press release)Oncolytics Biotech® Inc. Appoints Dr. Matt Coffey to the Role of President and CEO - PR Newswire (press release)
www.prnewswire.com - January 21 at 7:40 AM
BRIEF-Oncolytics Biotech names Matt Coffey CEOBRIEF-Oncolytics Biotech names Matt Coffey CEO
www.reuters.com - January 19 at 11:41 PM
Targovax announces appointment of Erik Digman Wiklund as CFO ... - GlobeNewswire (press release)Targovax announces appointment of Erik Digman Wiklund as CFO ... - GlobeNewswire (press release)
globenewswire.com - January 5 at 5:53 AM
Research Reports Initiated on Healthcare Stocks Immunovaccine, Oncolytics Biotech, and Theratechnologies - Baystreet.caResearch Reports Initiated on Healthcare Stocks Immunovaccine, Oncolytics Biotech, and Theratechnologies - Baystreet.ca
www.baystreet.ca - December 13 at 9:04 AM
Pioneers in Oncolytic Virus and Gene Therapy Fields Announce Formation of IGNITE Immunotherapy Inc., a Company ... - Business Wire (press release)Pioneers in Oncolytic Virus and Gene Therapy Fields Announce Formation of IGNITE Immunotherapy Inc., a Company ... - Business Wire (press release)
www.businesswire.com - December 12 at 7:09 PM

SEC Filings

Oncolytics Biotech (TSE:ONC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Oncolytics Biotech (TSE ONC) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.